GEN Exclusives

More »

GEN News Highlights

More »
Jul 21, 2009

Medicago and Genopole to Set Up Plant in France for Influenza Vaccine Production

  • Medicago and Genopole® biopark agreed to work together to build a facility to manufacture pandemic and seasonal influenza vaccines in France. They believe that it could complement France's existing domestic flu vaccine production infrastructure by offering surge capacity of vaccines before the first wave of a pandemic strikes.

    Construction is conditional upon Medicago's successful completion of a Phase I trial with its H5N1 pandemic influenza vaccine and a reasonable level of commitment by the French authorities to support this technology, the firms report. This agreement builds on a feasibility study that was completed this year to evaluate the economic and technological viability of a novel vaccine production facility in France.

    The facility will be based on Medicago's Proficia™ plant-based manufacturing technology and VLP vaccine technology on Genopole's site in Evry, France. It will initially produce pandemic and seasonal influenza vaccines. In the long-term it could be used for a broad range of vaccines and other biodefense-related products, according to the firms.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

New NIH Budget Proposal Leaves Many Confused and Unsettled

Do you think that using the so-called “mandatory budget funds” to pay for the proposed $825 million increase, as well as $1 billion of the NIH’s existing budget is a good idea?

More »